- Home
- SCLX vs RGS Comparison
SCLX vs RGS Comparison
Compare SCLX & RGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- RGS
- Stock Information
- Founded
- SCLX 2011
- RGS 1922
- Country
- SCLX United States
- RGS United States
- Employees
- SCLX N/A
- RGS N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- RGS Other Consumer Services
- Sector
- SCLX Health Care
- RGS Consumer Discretionary
- Exchange
- SCLX Nasdaq
- RGS Nasdaq
- Market Cap
- SCLX 61.5M
- RGS 54.5M
- IPO Year
- SCLX N/A
- RGS 1991
- Fundamental
- Price
- SCLX $0.33
- RGS $21.61
- Analyst Decision
- SCLX Strong Buy
- RGS
- Analyst Count
- SCLX 4
- RGS 0
- Target Price
- SCLX $14.00
- RGS N/A
- AVG Volume (30 Days)
- SCLX 184.3K
- RGS 33.6K
- Earning Date
- SCLX 03-11-2025
- RGS 02-12-2025
- Dividend Yield
- SCLX N/A
- RGS N/A
- EPS Growth
- SCLX N/A
- RGS N/A
- EPS
- SCLX N/A
- RGS 40.46
- Revenue
- SCLX $55,152,000.00
- RGS $191,336,000.00
- Revenue This Year
- SCLX $24.19
- RGS N/A
- Revenue Next Year
- SCLX $109.90
- RGS N/A
- P/E Ratio
- SCLX N/A
- RGS $0.59
- Revenue Growth
- SCLX 22.02
- RGS N/A
- 52 Week Low
- SCLX $0.32
- RGS $3.87
- 52 Week High
- SCLX $2.63
- RGS $35.50
- Technical
- Relative Strength Index (RSI)
- SCLX 30.09
- RGS 42.67
- Support Level
- SCLX $0.33
- RGS $23.32
- Resistance Level
- SCLX $0.36
- RGS $24.45
- Average True Range (ATR)
- SCLX 0.03
- RGS 1.86
- MACD
- SCLX -0.00
- RGS -0.29
- Stochastic Oscillator
- SCLX 8.90
- RGS 13.68
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About RGS Regis Corporation
Regis Corp owns, franchises, and operates beauty salons throughout North America and the United Kingdom. The company's locations provide salon products and services to the mass market, including haircutting, styling, and hair coloring. The vast majority of Regis' salons are in strip malls, shopping centers, and Wal-Mart stores in North America and serve price-conscious customers. The company derives the majority of its revenue from these locations. The sale of products also contributes a relatively significant percentage of total sales. Regis also operates a smaller portfolio of premium salons across North America and the U.K. The company's majority brands include SmartStyle, Cost Cutters, and Supercuts.